비스타젠 테라퓨틱스(VTGN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.27 (+0.49%), 시가총액 $0.02B, 52주 범위 $0.51 ~ $4.90.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's product pipeline includes Fasedienol, an investigational pherine nasal spray that is in Phase III clinical trial for the treatment of anxiety in adults with social anxiety disorder; and Itruvone, an odorless synthetic investigational neuroactive pherine nasal spray, which is in Phase II clinical trial to treat major depressive disorder. It also develops PH80, an odorless and tasteless synthetic investigational pherine nasal spray that is in Phase II clinical trial for the treatment of vasomotor sy
비스타젠 테라퓨틱스의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.
비스타젠 테라퓨틱스의 현재 주가는 $0.27 (+0.49%)입니다. BlackQuant에서 실시간 시세와 차트를 확인할 수 있습니다.
비스타젠 테라퓨틱스의 시가총액은 약 $0.02B입니다.
Vistagen Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of therapies for neuropsychiatric and neurological disorders. The company's pr